P0860 Long-term outcomes of extended versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission: 3-year follow-up of the randomized controlled LADI trial
Martine Devillers(Erasmus MC), Frank Hoentjen(Radboud University Nijmegen), Zlatan Mujagic(Maastricht University Medical Centre), Adriaan C.I.T.L. Tan(Canisius-Wilhelmina Ziekenhuis), Rosalie C. Mallant–Hent, Alexander Bodelier(Amphia Ziekenhuis), Frank H.J. Wolfhagen(Albert Schweitzer Ziekenhuis), Robert West(The Behaviouralist (United Kingdom)), Henri Braat(Medisch Spectrum Twente), N de Boer(University of Amsterdam), A Van Bodegraven(Zuyderland Medisch Centrum), J van der Woude(Erasmus University Rotterdam), Maurice Lutgens(Elisabeth-TweeSteden Ziekenhuis), Fenna M. Jansen(Radboud University Nijmegen), Tessa E H Römkens(Jeroen Bosch Ziekenhuis), Pieter ter Borg(Ikazia Ziekenhuis), Paul J. Boekema(Radboud University Nijmegen), Nathan den Broeder(Radboud University Nijmegen), Robbart van Linschoten(Qatar Orthopaedic and Sports Medicine Hospital), Jeroen M. Jansen(OLVG), Ingrid Gisbertz(Ziekenhuis Bernhoven), Debora de Jong(University of Groningen), Annemarie de Vries(Erasmus University Rotterdam), Sanne Jansen(Reinier de Graaf Hospital), Bas Oldenburg(University Medical Center Utrecht), A van der Meulen-de Jong(Leiden University Medical Center), L van Lierop(University of Alberta)
Cited by 0
Related Papers
Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity
|Science|2016|2k
Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases
|Nature Genetics|2019|1.6k
Cassini Observes the Active South Pole of Enceladus
|Science|2006|1.2k